K. SHITARA Et Al. , "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial," LANCET , vol.392, no.10142, pp.123-133, 2018
SHITARA, K. Et Al. 2018. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. LANCET , vol.392, no.10142 , 123-133.
SHITARA, K., Ozguroglu, M., BANG, Y., DI BARTOLOMEO, M., MANDALA, M., RYU, M., ... FORNARO, L.(2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. LANCET , vol.392, no.10142, 123-133.
SHITARA, Kohei Et Al. "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial," LANCET , vol.392, no.10142, 123-133, 2018
SHITARA, Kohei Et Al. "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial." LANCET , vol.392, no.10142, pp.123-133, 2018
SHITARA, K. Et Al. (2018) . "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial." LANCET , vol.392, no.10142, pp.123-133.
@article{article, author={Kohei SHITARA Et Al. }, title={Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial}, journal={LANCET}, year=2018, pages={123-133} }